Industry Daily Summary
Industry Daily Summary: What Happened on November 14, 2026
China draws licensing interest for more novel biotech assets
The Cell and Gene Therapy Catapult has begun looking for a successor to chief executive Matthew Durdy.
Today in brief
A BioCentury-BayHelix summit analysis described a shift in buyer interest toward China-based biotech assets with potential to deliver novel therapeutic advances.1 It compared that interest with earlier attention to lower-cost assets that might produce data faster.1
The Cell and Gene Therapy Catapult hired Coulter Partners to find a successor to chief executive Matthew Durdy, who plans to retire in June 2027.2
China licensing interest shifts toward novel assets
A BioCentury-BayHelix summit analysis described a shift in licensing interest toward China-based assets with potential to offer valuable therapeutic advances, away from lower-cost assets that might deliver data faster.1
The review covered therapeutic-product deals involving a China-based biotech licensor and a licensee anywhere in the world, from January 1, 2023, through September 30, 2026.1
Cell and Gene Therapy Catapult seeks Durdy’s successor
The Cell and Gene Therapy Catapult contracted executive-search firm Coulter Partners to find its next chief executive.2 Durdy plans to retire in June 2027 after leading the organization for seven years and working there for 15.2
Durdy said the UK has moved from strong cell and gene therapy research with little related industry to developing and manufacturing therapies at home for patients.2 The Catapult was established in 2012.2